181 related articles for article (PubMed ID: 38826812)
1. Bibliometric analysis of most cited Peyronie's disease and its management publications.
Şahin MF; Doğan Ç; Akgül M; Yazıcı CM; Şeramet S; Dayısoylu HS
Front Surg; 2024; 11():1336391. PubMed ID: 38826812
[TBL] [Abstract][Full Text] [Related]
2. Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol.
Abdel Raheem A; Johnson M; Abdel-Raheem T; Capece M; Ralph D
Sex Med Rev; 2017 Oct; 5(4):529-535. PubMed ID: 28874327
[TBL] [Abstract][Full Text] [Related]
3. Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Patients and Their Female Partners.
Goldstein I; Knoll LD; Lipshultz LI; Smith T; Kaufman GJ; McMahon CG
Sex Med; 2017 Jun; 5(2):e124-e130. PubMed ID: 28395998
[TBL] [Abstract][Full Text] [Related]
4. The 100 most-cited publications on Peyronie's disease: a bibliometric analysis and visualization study.
Gao D; Shen Y; Tang B; Ma Z; Chen D; Yu X; Li G; Chang D
Int J Impot Res; 2024 Apr; 36(2):110-117. PubMed ID: 37198341
[TBL] [Abstract][Full Text] [Related]
5. Impact of the Advent of Collagenase Clostridium Histolyticum on the Surgical Management of Peyronie's Disease: A Population-Based Analysis.
Sukumar S; Pijush DB; Brandes S
J Sex Med; 2020 Jan; 17(1):111-116. PubMed ID: 31759930
[TBL] [Abstract][Full Text] [Related]
6. Collagenase clostridium histolyticum: a novel medical treatment for Peyronie's disease.
Abdel Raheem A; Johnson M; Ralph D; Garaffa G
Minerva Urol Nefrol; 2018 Aug; 70(4):380-385. PubMed ID: 29761688
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: An Evidence-Based Analysis.
Cao D; Li J; Lu Y; Huang Y; Chen B; Chen Z; Shen Y; Liu L; Wei Q
Front Med (Lausanne); 2022; 9():780956. PubMed ID: 35252236
[TBL] [Abstract][Full Text] [Related]
8. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.
Levine LA; Cuzin B; Mark S; Gelbard MK; Jones NA; Liu G; Kaufman GJ; Tursi JP; Ralph DJ
J Sex Med; 2015 Jan; 12(1):248-58. PubMed ID: 25388099
[TBL] [Abstract][Full Text] [Related]
9. Self-report and Clinical Response to Peyronie's Disease Treatment: Peyronie's Disease Questionnaire Results From 2 Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies.
Hellstrom WJ; Feldman RA; Coyne KS; Kaufman GJ; Smith TM; Tursi JP; Rosen RC
Urology; 2015 Aug; 86(2):291-8. PubMed ID: 26199168
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Collagenase Clostridium histolyticum (Xiapex
Cocci A; Di Maida F; Russo GI; Capogrosso P; Francesco L; Rizzo M; Di Mauro M; Salonia A; Cito G; Falcone M; Romano A; Polloni G; Martinez-Salamanca JI; Fernández-Pascual E; Minervini A; Mondaini N
Clin Drug Investig; 2020 Jun; 40(6):583-588. PubMed ID: 32342279
[TBL] [Abstract][Full Text] [Related]
11. Peyronie's disease: contemporary review of non-surgical treatment.
Levine LA
Transl Androl Urol; 2013 Mar; 2(1):39-44. PubMed ID: 26816722
[TBL] [Abstract][Full Text] [Related]
12. Current Strategies in the Management of Peyronie's Disease (PD)-Results of a Survey of 401 Sexual Medicine Experts Across Europe.
Porst H; Burri A;
J Sex Med; 2019 Jun; 16(6):901-908. PubMed ID: 31103483
[TBL] [Abstract][Full Text] [Related]
13. Collagenase Clostridium histolyticum for the Treatment of Peyronie's Disease: The Development of This Novel Pharmacologic Approach.
Gelbard MK; Chagan L; Tursi JP
J Sex Med; 2015 Jun; 12(6):1481-9. PubMed ID: 25940867
[TBL] [Abstract][Full Text] [Related]
14. A survey of exposure to the use of Xiaflex for the treatment of Peyronie's disease among United States urology residency programs.
Loloi J; Schuppe K; Reddy RV; Rahman F; Bernstein A; Reddy P; Kulkarni N; Masterson T; Ramasamy R
Int J Impot Res; 2024 Apr; 36(2):155-159. PubMed ID: 37865716
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie's Disease.
Goldstein I; Lipshultz LI; McLane M; Hu Y; Xiang Q; Liu G; Vijayan S; Gelbard MK
J Urol; 2020 Jun; 203(6):1191-1197. PubMed ID: 31922462
[TBL] [Abstract][Full Text] [Related]
16. Review of Management Options for Patients With Atypical Peyronie's Disease.
Yafi FA; Hatzichristodoulou G; DeLay KJ; Hellstrom WJ
Sex Med Rev; 2017 Apr; 5(2):211-221. PubMed ID: 27544298
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of local injections treatments for Peyronie's disease: Review of the literature].
Rod X; Akakpo W; Roupret M
Prog Urol; 2021 Dec; 31(16):1072-1079. PubMed ID: 34148769
[TBL] [Abstract][Full Text] [Related]
18. Collagenase Clostridium histolyticum in the management of Peyronie's disease: a review of the evidence.
Traore EJ; Wang W; Yafi FA; Hellstrom WJ
Ther Adv Urol; 2016 Jun; 8(3):192-202. PubMed ID: 27247629
[TBL] [Abstract][Full Text] [Related]
19. Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis.
Hellstrom WJG; Tue Nguyen HM; Alzweri L; Chung A; Virasoro R; Tapscott A; Ziegelmann M; Trost L; Gelbard M
J Urol; 2019 Apr; 201(4):777-782. PubMed ID: 30672843
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies.
Lipshultz LI; Goldstein I; Seftel AD; Kaufman GJ; Smith TM; Tursi JP; Burnett AL
BJU Int; 2015 Oct; 116(4):650-6. PubMed ID: 25711400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
